Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

1
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Journal Title Analysis
Category Analysis

Results Analysis

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Category

Show more Refine

For: Phillips AN, Bansi-Matharu L, Shahmanesh M, Hargreaves JR, Smith J, Revill P, Sibanda E, Ehrenkranz P, Sikwese K, Rodger A, Lundgren JD, Gilks CF, Godfrey C, Cowan F, Cambiano V. Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis. Lancet Glob Health 2023;11:e1648-e1657. [PMID: 37734807 DOI: 10.1016/s2214-109x(23)00383-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 07/23/2023] [Accepted: 08/04/2023] [Indexed: 09/23/2023]

For:	Phillips AN, Bansi-Matharu L, Shahmanesh M, Hargreaves JR, Smith J, Revill P, Sibanda E, Ehrenkranz P, Sikwese K, Rodger A, Lundgren JD, Gilks CF, Godfrey C, Cowan F, Cambiano V. Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis. Lancet Glob Health 2023;11:e1648-e1657. [PMID: 37734807 DOI: 10.1016/s2214-109x(23)00383-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 07/23/2023] [Accepted: 08/04/2023] [Indexed: 09/23/2023]

Number

Cited by Other Article(s)

Stranix-Chibanda L, Mhembere T. Unrestricted access to tenofovir, lamivudine, and dolutegravir as pre-exposure or post-exposure prophylaxis in community settings. Lancet Glob Health 2023;11:e1494-e1495. [PMID: 37734786 DOI: 10.1016/s2214-109x(23)00423-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Accepted: 08/29/2023] [Indexed: 09/23/2023]